Novartis dispatches two more cancer drug castoffs to a partner in China
Novartis is sending two more of its oncology castoffs to a China biotech.
The pharma giant has out-licensed global rights to two of its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
